191. Werner syndrome Clinical trials / Disease details

Clinical trials : 3 / Drugs : 4 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 5

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031190141	19/03/2021	27/11/2019	Cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome	Prospective, single-center, cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome - EMPOWER	Werner syndrome Werner syndrome;C16.320.925 / C18.452.284.960	Subjects ingest oral capsules of NR (nicotinamide riboside) once daily (total daily dose: nicotinamide riboside 1000 mg).	Yokote Koutaro	NULL	Recruiting	>= 20age old	Not applicable	Both	30	Phase 1-2	Japan
2	NCT04512963 (ClinicalTrials.gov)	August 24, 2020	6/8/2020	Phase I Study of Progerinin in Healthy Volunteers	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers	Hutchinson-Gilford Progeria Syndrome;Werner Syndrome	Drug: Progerinin;Drug: Placebo	PRG Science & Technology Co., Ltd.	Amarex Clinical Research	Completed	18 Years	45 Years	All	64	Phase 1	United States
3	NCT00004815 (ClinicalTrials.gov)	May 1992	24/2/2000	Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome		Werner's Syndrome	Drug: growth hormone	National Center for Research Resources (NCRR)	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);University of Texas	Completed	N/A	N/A	Both	1	N/A	NULL